TMEM259
gene geneOn this page
Also known as MGC4022ASBABP1MBRL
Summary
TMEM259 (transmembrane protein 259, HGNC:17039) is a protein-coding gene on chromosome 19p13.3, encoding Membralin (Q4ZIN3). May have a role in the ERAD pathway required for clearance of misfolded proteins in the endoplasmic reticulum (ER).
Predicted to be involved in positive regulation of ERAD pathway and response to endoplasmic reticulum stress. Predicted to be located in endoplasmic reticulum membrane. Predicted to be active in endoplasmic reticulum.
Source: NCBI Gene 91304 — RefSeq curated summary.
At a glance
- GWAS associations: 2
- Clinical variants (ClinVar): 135 total
- MANE Select transcript:
NM_001033026
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:17039 |
| Approved symbol | TMEM259 |
| Name | transmembrane protein 259 |
| Location | 19p13.3 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | MGC4022, ASBABP1, MBRL |
| Ensembl gene | ENSG00000182087 |
| Ensembl biotype | protein_coding |
| OMIM | 611011 |
| Entrez | 91304 |
Gene structure
Transcript identifiers
Ensembl transcripts: 28 — 21 protein_coding, 6 retained_intron, 1 nonsense_mediated_decay
ENST00000333175, ENST00000356663, ENST00000586250, ENST00000586285, ENST00000586704, ENST00000589055, ENST00000589831, ENST00000592052, ENST00000592590, ENST00000592618, ENST00000593068, ENST00000607316, ENST00000902894, ENST00000902895, ENST00000902896, ENST00000902897, ENST00000902898, ENST00000902899, ENST00000902900, ENST00000902901, ENST00000902902, ENST00000902903, ENST00000925026, ENST00000925027, ENST00000925028, ENST00000925029, ENST00000941279, ENST00000941280
RefSeq mRNA: 2 — MANE Select: NM_001033026
NM_001033026, NM_033420
CCDS: CCDS12052, CCDS32862
Canonical transcript exons
ENST00000356663 — 11 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001350193 | 1012066 | 1012188 |
| ENSE00002806299 | 1009653 | 1010895 |
| ENSE00003695749 | 1014192 | 1014473 |
| ENSE00003696665 | 1011580 | 1011663 |
| ENSE00003698514 | 1011367 | 1011499 |
| ENSE00003699306 | 1013241 | 1013340 |
| ENSE00003700453 | 1012463 | 1012573 |
| ENSE00003700776 | 1011741 | 1011798 |
| ENSE00003700834 | 1011096 | 1011195 |
| ENSE00003702315 | 1011892 | 1011992 |
| ENSE00003850202 | 1020772 | 1021123 |
Expression profiles
Bgee: expression breadth ubiquitous, 262 present calls, max score 98.99.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 86.0044 / max 1269.6346, expressed in 1827 samples.
FANTOM5 promoters (1 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 177958 | 86.0044 | 1827 |
Top tissues by expression
292 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| adenohypophysis | UBERON:0002196 | 98.99 | gold quality |
| granulocyte | CL:0000094 | 98.97 | gold quality |
| metanephros cortex | UBERON:0010533 | 98.93 | gold quality |
| right uterine tube | UBERON:0001302 | 98.87 | gold quality |
| right hemisphere of cerebellum | UBERON:0014890 | 98.84 | gold quality |
| right lobe of thyroid gland | UBERON:0001119 | 98.79 | gold quality |
| left lobe of thyroid gland | UBERON:0001120 | 98.77 | gold quality |
| small intestine Peyer’s patch | UBERON:0003454 | 98.76 | gold quality |
| tibial nerve | UBERON:0001323 | 98.72 | gold quality |
| endocervix | UBERON:0000458 | 98.67 | gold quality |
| mucosa of stomach | UBERON:0001199 | 98.66 | gold quality |
| body of stomach | UBERON:0001161 | 98.65 | gold quality |
| left uterine tube | UBERON:0001303 | 98.64 | gold quality |
| body of uterus | UBERON:0009853 | 98.59 | gold quality |
| transverse colon | UBERON:0001157 | 98.58 | gold quality |
| cerebellar hemisphere | UBERON:0002245 | 98.57 | gold quality |
| skin of abdomen | UBERON:0001416 | 98.56 | gold quality |
| lower esophagus mucosa | UBERON:0035834 | 98.56 | gold quality |
| ectocervix | UBERON:0012249 | 98.53 | gold quality |
| muscle layer of sigmoid colon | UBERON:0035805 | 98.53 | gold quality |
| right ovary | UBERON:0002118 | 98.52 | gold quality |
| skin of leg | UBERON:0001511 | 98.48 | gold quality |
| apex of heart | UBERON:0002098 | 98.48 | gold quality |
| left ovary | UBERON:0002119 | 98.45 | gold quality |
| minor salivary gland | UBERON:0001830 | 98.43 | gold quality |
| esophagogastric junction muscularis propria | UBERON:0035841 | 98.43 | gold quality |
| cerebellar cortex | UBERON:0002129 | 98.42 | gold quality |
| right lung | UBERON:0002167 | 98.42 | gold quality |
| left adrenal gland cortex | UBERON:0035825 | 98.38 | gold quality |
| lower esophagus muscularis layer | UBERON:0035833 | 98.38 | gold quality |
Single-cell (SCXA)
Detected in 1 experiment(s), a significant marker in 1.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | yes | 8.06 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
23 targeting TMEM259, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-LET-7A-3P | 100.00 | 74.03 | 3932 |
| HSA-LET-7B-3P | 100.00 | 74.08 | 3913 |
| HSA-LET-7F-1-3P | 100.00 | 74.02 | 3928 |
| HSA-MIR-98-3P | 100.00 | 74.08 | 3907 |
| HSA-MIR-381-3P | 99.93 | 71.87 | 2854 |
| HSA-MIR-300 | 99.92 | 71.76 | 2856 |
| HSA-MIR-3121-3P | 99.82 | 71.96 | 3630 |
| HSA-MIR-4679 | 99.76 | 69.19 | 1229 |
| HSA-MIR-3934-3P | 99.76 | 65.51 | 1351 |
| HSA-MIR-10394-5P | 99.65 | 66.83 | 1852 |
| HSA-MIR-1205 | 99.65 | 66.76 | 1826 |
| HSA-MIR-6757-3P | 99.63 | 66.88 | 1089 |
| HSA-MIR-7112-5P | 99.59 | 65.76 | 104 |
| HSA-MIR-1324 | 99.46 | 66.57 | 1302 |
| HSA-MIR-6853-3P | 99.36 | 70.79 | 1558 |
| HSA-MIR-1206 | 99.30 | 69.32 | 1016 |
| HSA-MIR-3199 | 99.17 | 65.19 | 696 |
| HSA-MIR-8052 | 99.17 | 65.01 | 719 |
| HSA-MIR-328-5P | 99.08 | 64.65 | 1000 |
| HSA-MIR-6749-3P | 99.00 | 65.73 | 1443 |
| HSA-MIR-1227-5P | 98.65 | 65.32 | 1549 |
| HSA-MIR-4252 | 98.45 | 66.37 | 987 |
| HSA-MIR-4660 | 97.79 | 67.44 | 1328 |
Literature-anchored findings (GeneRIF, showing 2)
- genomic organization and expression (membralin) (PMID:12638133)
- Study provides first characterization of human membralin and suggests that membralin is a novel tumor-associated marker in ovarian serous carcinomas. (PMID:16084606)
Cross-species orthologs
5 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | tmem259 | ENSDARG00000060442 |
| mus_musculus | Tmem259 | ENSMUSG00000013858 |
| rattus_norvegicus | Tmem259 | ENSRNOG00000012808 |
| drosophila_melanogaster | CG8405 | FBGN0034071 |
| caenorhabditis_elegans | WBGENE00021985 |
Paralogs (1): NUF2 (ENSG00000143228)
Protein
Protein identifiers
Membralin — Q4ZIN3 (reviewed: Q4ZIN3)
Alternative names: Transmembrane protein 259
All UniProt accessions (5): A0A0A0MTU3, Q4ZIN3, U3KPU1, U3KPY4, U3KQQ5
UniProt curated annotations — full annotation on UniProt →
Function. May have a role in the ERAD pathway required for clearance of misfolded proteins in the endoplasmic reticulum (ER). Promotes survival of motor neurons, probably by protecting against ER stress.
Subunit / interactions. Interacts with ERLIN2.
Subcellular location. Endoplasmic reticulum membrane.
Similarity. Belongs to the membralin family.
Isoforms (2)
| UniProt ID | Names | Canonical? |
|---|---|---|
| Q4ZIN3-1 | 1, Long, Membralin-1 | yes |
| Q4ZIN3-2 | 2, Short, Membralin-2, Membralin-3 |
RefSeq proteins (2): NP_001028198, NP_219488 (=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR019144 | Membralin | Family |
Pfam: PF09746
UniProt features (17 total): transmembrane region 4, compositionally biased region 3, region of interest 3, modified residue 2, splice variant 2, initiator methionine 1, chain 1, glycosylation site 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q4ZIN3-F1 | 65.48 | 0.12 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Post-translational modifications (2): 2, 29
Glycosylation sites (1): 189
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 149 (showing top):
TGGTGCT_MIR29A_MIR29B_MIR29C, ELVIDGE_HYPOXIA_DN, MODULE_52, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP, LFA1_Q6, GOBP_RESPONSE_TO_ENDOPLASMIC_RETICULUM_STRESS, GOBP_POSITIVE_REGULATION_OF_PROTEIN_CATABOLIC_PROCESS, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, PATIL_LIVER_CANCER, GTGCCTT_MIR506, RICKMAN_METASTASIS_DN, GOBP_REGULATION_OF_CATABOLIC_PROCESS, GOBP_POSITIVE_REGULATION_OF_CATABOLIC_PROCESS, GOBP_REGULATION_OF_RESPONSE_TO_STRESS
GO Biological Process (2): response to endoplasmic reticulum stress (GO:0034976), positive regulation of ERAD pathway (GO:1904294)
GO Molecular Function (0):
GO Cellular Component (3): endoplasmic reticulum (GO:0005783), endoplasmic reticulum membrane (GO:0005789), membrane (GO:0016020)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| cellular response to stress | 1 |
| ERAD pathway | 1 |
| positive regulation of proteasomal protein catabolic process | 1 |
| regulation of ERAD pathway | 1 |
| positive regulation of response to endoplasmic reticulum stress | 1 |
| cytoplasm | 1 |
| endomembrane system | 1 |
| intracellular membrane-bounded organelle | 1 |
| organelle membrane | 1 |
| nuclear outer membrane-endoplasmic reticulum membrane network | 1 |
| endoplasmic reticulum subcompartment | 1 |
| cellular anatomical structure | 1 |
Protein interactions and networks
STRING
888 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| TMEM259 | TMUB1 | Q9BVT8 | 851 |
| TMEM259 | TMUB2 | Q71RG4 | 663 |
| TMEM259 | RNF185 | Q96GF1 | 654 |
| TMEM259 | MED16 | Q9Y2X0 | 546 |
| TMEM259 | FAM174C | Q9BVV8 | 537 |
| TMEM259 | EMC1 | Q8N766 | 522 |
| TMEM259 | SEL1L | Q9UBV2 | 520 |
| TMEM259 | TMEM186 | Q96B77 | 514 |
| TMEM259 | NGLY1 | Q96IV0 | 505 |
| TMEM259 | C6orf120 | Q7Z4R8 | 504 |
| TMEM259 | PLPPR3 | Q6T4P5 | 499 |
| TMEM259 | CACHD1 | Q5VU97 | 476 |
| TMEM259 | RBIS | Q8N0T1 | 462 |
| TMEM259 | NSFL1C | Q9UNZ2 | 449 |
| TMEM259 | STT3A | P46977 | 440 |
| TMEM259 | RNF170 | Q96K19 | 440 |
IntAct
105 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| BCL2 | BCL2L11 | psi-mi:“MI:0914”(association) | 0.930 |
| ERLIN2 | ERLIN1 | psi-mi:“MI:0914”(association) | 0.740 |
| VMA12 | ATP6AP2 | psi-mi:“MI:0914”(association) | 0.640 |
| B3GAT3 | GOLIM4 | psi-mi:“MI:0914”(association) | 0.640 |
| ANKRD46 | ATRN | psi-mi:“MI:0914”(association) | 0.640 |
| ASPH | STXBP3 | psi-mi:“MI:0914”(association) | 0.640 |
| CANX | PGRMC1 | psi-mi:“MI:0914”(association) | 0.570 |
| YIPF3 | TMEM120B | psi-mi:“MI:0914”(association) | 0.530 |
| EMC6 | EMC8 | psi-mi:“MI:0914”(association) | 0.530 |
| B3GALT2 | LTN1 | psi-mi:“MI:0914”(association) | 0.530 |
| SPSB2 | ARHGEF10 | psi-mi:“MI:0914”(association) | 0.530 |
| DIPK1A | TMEM259 | psi-mi:“MI:0914”(association) | 0.530 |
| ABHD14A | TMEM259 | psi-mi:“MI:0914”(association) | 0.530 |
| SPSB4 | ARHGEF10 | psi-mi:“MI:0914”(association) | 0.530 |
| ANKH | FAM234B | psi-mi:“MI:0914”(association) | 0.530 |
| TMEM259 | PLOD3 | psi-mi:“MI:0915”(physical association) | 0.400 |
| TMEM223 | TMEM259 | psi-mi:“MI:0915”(physical association) | 0.400 |
| TMEM259 | ADRB2 | psi-mi:“MI:0915”(physical association) | 0.370 |
| ESYT2 | psi-mi:“MI:0914”(association) | 0.350 | |
| E5 | ESYT2 | psi-mi:“MI:0914”(association) | 0.350 |
| HAX1 | psi-mi:“MI:0914”(association) | 0.350 | |
| CNR2 | ILVBL | psi-mi:“MI:0914”(association) | 0.350 |
| STYK1 | XPO1 | psi-mi:“MI:0914”(association) | 0.350 |
| STYK1 | MYO1C | psi-mi:“MI:0914”(association) | 0.350 |
| APOA2 | TMEM131L | psi-mi:“MI:0914”(association) | 0.350 |
| GPR88 | POTEF | psi-mi:“MI:0914”(association) | 0.350 |
| SPSB4 | CCDC85C | psi-mi:“MI:0914”(association) | 0.350 |
| OR6T1 | PSMD11 | psi-mi:“MI:0914”(association) | 0.350 |
| CLSTN1 | NOP56 | psi-mi:“MI:0914”(association) | 0.350 |
| MS4A15 | ABCD4 | psi-mi:“MI:0914”(association) | 0.350 |
BioGRID (155): TMEM259 (Affinity Capture-MS), TMEM259 (Affinity Capture-MS), TMEM259 (Affinity Capture-MS), TMEM259 (Affinity Capture-MS), TMEM259 (Affinity Capture-MS), TMEM259 (Affinity Capture-MS), TMEM259 (Affinity Capture-MS), TMEM259 (Affinity Capture-MS), TMEM259 (Affinity Capture-MS), TMEM259 (Affinity Capture-MS), TMEM259 (Affinity Capture-MS), TMEM259 (Affinity Capture-MS), TMEM259 (Affinity Capture-MS), TMEM259 (Affinity Capture-MS), TMEM259 (Affinity Capture-MS)
ESM2 similar proteins: A0A494C086, A0A494C0Z2, A0A494C191, A0JPH4, A6NHP3, A6NIY4, A6NJR5, A6NLX3, A6NNV3, A6QLI5, B0BNE4, O08918, O60543, O70302, O75916, P0CI01, P0DTA3, P0DUD1, P0DUD2, P0DUD3, P0DUD4, P0DUX0, P0DUX1, P0DV79, P24864, P39949, P49805, Q12967, Q495Y7, Q495Y8, Q4VXA5, Q4ZIN3, Q5IBH6, Q5IBH7, Q5MJ70, Q5SYB0, Q5XIQ2, Q5ZJR9, Q61457, Q6AYG1
Diamond homologs: Q4ZIN3, Q8CIV2
SIGNOR signaling
0 interactions.
Enriched among interaction partners
Reactome pathways and GO biological processes over-represented among this gene’s 149 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.
Reactome pathways:
| Pathway | Partners | Fold | FDR |
|---|---|---|---|
| Defective CFTR causes cystic fibrosis | 7 | 16.4× | 1e-04 |
| AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) | 7 | 14.4× | 1e-04 |
| ABC-family protein mediated transport | 7 | 9.1× | 1e-03 |
| Class A/1 (Rhodopsin-like receptors) | 9 | 7.1× | 6e-04 |
| Transport of small molecules | 16 | 4.3× | 2e-04 |
GO biological processes:
| GO term | Partners | Fold | FDR |
|---|---|---|---|
| ERAD pathway | 7 | 10.1× | 5e-03 |
| transmembrane transport | 7 | 9.4× | 5e-03 |
Disease & clinical
Clinical variants and AI predictions
ClinVar
135 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 115 |
| Likely benign | 7 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
1750 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 19:1010891:GAATG:G | acceptor_gain | 1.0000 |
| 19:1010892:AATG:A | acceptor_gain | 1.0000 |
| 19:1010893:ATG:A | acceptor_gain | 1.0000 |
| 19:1010894:TG:T | acceptor_gain | 1.0000 |
| 19:1010896:C:A | acceptor_loss | 1.0000 |
| 19:1010896:C:CC | acceptor_gain | 1.0000 |
| 19:1010900:G:T | acceptor_gain | 1.0000 |
| 19:1011090:CCTCA:C | donor_loss | 1.0000 |
| 19:1011091:CTCA:C | donor_loss | 1.0000 |
| 19:1011093:CA:C | donor_loss | 1.0000 |
| 19:1011094:A:C | donor_loss | 1.0000 |
| 19:1011193:AACCT:A | acceptor_loss | 1.0000 |
| 19:1011194:ACCT:A | acceptor_loss | 1.0000 |
| 19:1011195:CCTGC:C | acceptor_loss | 1.0000 |
| 19:1011197:T:A | acceptor_loss | 1.0000 |
| 19:1011362:CTCA:C | donor_loss | 1.0000 |
| 19:1011364:CA:C | donor_loss | 1.0000 |
| 19:1011365:A:AC | donor_gain | 1.0000 |
| 19:1011365:ACCG:A | donor_gain | 1.0000 |
| 19:1011366:C:CC | donor_gain | 1.0000 |
| 19:1011366:CCG:C | donor_gain | 1.0000 |
| 19:1011366:CCGC:C | donor_gain | 1.0000 |
| 19:1011366:CCGCA:C | donor_gain | 1.0000 |
| 19:1011495:CATCC:C | acceptor_gain | 1.0000 |
| 19:1011498:CCCTG:C | acceptor_loss | 1.0000 |
| 19:1011499:CCTGC:C | acceptor_loss | 1.0000 |
| 19:1011500:CTG:C | acceptor_loss | 1.0000 |
| 19:1011501:T:G | acceptor_loss | 1.0000 |
| 19:1011664:C:CC | acceptor_gain | 1.0000 |
| 19:1011735:ACTC:A | donor_loss | 1.0000 |
AlphaMissense
4058 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 19:1010861:A:G | L451P | 1.000 |
| 19:1011121:A:G | L431P | 1.000 |
| 19:1011147:G:C | F422L | 1.000 |
| 19:1011147:G:T | F422L | 1.000 |
| 19:1011149:A:G | F422L | 1.000 |
| 19:1011168:G:C | F415L | 1.000 |
| 19:1011168:G:T | F415L | 1.000 |
| 19:1011170:A:G | F415L | 1.000 |
| 19:1011374:A:G | W404R | 1.000 |
| 19:1011374:A:T | W404R | 1.000 |
| 19:1011431:A:G | W385R | 1.000 |
| 19:1011431:A:T | W385R | 1.000 |
| 19:1011499:C:T | G362E | 1.000 |
| 19:1011580:C:G | G362R | 1.000 |
| 19:1011580:C:T | G362R | 1.000 |
| 19:1011585:A:G | L360P | 1.000 |
| 19:1011585:A:T | L360H | 1.000 |
| 19:1011588:G:T | A359D | 1.000 |
| 19:1011591:A:T | L358Q | 1.000 |
| 19:1011657:A:G | L336P | 1.000 |
| 19:1011751:G:C | F330L | 1.000 |
| 19:1011751:G:T | F330L | 1.000 |
| 19:1011753:A:G | F330L | 1.000 |
| 19:1011776:A:G | L322P | 1.000 |
| 19:1011779:A:G | L321P | 1.000 |
| 19:1011790:G:C | S317R | 1.000 |
| 19:1011790:G:T | S317R | 1.000 |
| 19:1011792:T:G | S317R | 1.000 |
| 19:1011952:A:C | F294L | 1.000 |
| 19:1011952:A:T | F294L | 1.000 |
dbSNP variants (sampled 300 via entrez): RS1000026779 (19:1016156 G>A), RS1000078217 (19:1010539 G>A,C), RS1000481993 (19:1009991 C>G), RS1000726421 (19:1022781 T>C), RS1000906907 (19:1021138 C>T), RS1000919581 (19:1019745 G>A), RS1001085250 (19:1015108 G>A), RS1001217364 (19:1009352 T>C), RS1001468570 (19:1020403 C>T), RS1001476293 (19:1016536 C>T), RS1001689526 (19:1022868 T>C,G), RS1001770523 (19:1015755 A>C,G), RS1001857768 (19:1015683 T>A), RS1001910049 (19:1015525 A>G), RS1002074005 (19:1019792 C>T)
Disease associations
OMIM: gene MIM:611011 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
2 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST004617_129 | Eosinophil percentage of granulocytes | 5.000000e-09 |
| GCST004621_203 | Red cell distribution width | 1.000000e-12 |
EFO canonical traits (2, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0007996 | eosinophil percentage of granulocytes |
| EFO:0009188 | Red cell distribution width |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
32 total (human), top 30 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| Air Pollutants | increases expression, affects cotreatment, increases abundance, increases oxidation, affects expression | 3 |
| Benzo(a)pyrene | decreases expression, increases methylation, increases mutagenesis | 3 |
| Particulate Matter | increases abundance, increases expression, affects cotreatment, affects expression | 3 |
| sodium arsenite | increases expression | 2 |
| Ozone | affects cotreatment, increases oxidation, increases abundance, affects expression | 2 |
| Cyclosporine | decreases expression | 2 |
| aristolochic acid I | increases expression | 1 |
| testosterone enanthate | affects expression | 1 |
| triphenyl phosphate | affects expression | 1 |
| alpha-pinene | increases oxidation, increases abundance, affects cotreatment | 1 |
| trichostatin A | decreases expression | 1 |
| beta-lapachone | decreases expression | 1 |
| cobaltous chloride | increases expression | 1 |
| methacrylaldehyde | affects cotreatment, increases oxidation, increases abundance | 1 |
| MT19c compound | decreases expression | 1 |
| Zoledronic Acid | increases expression | 1 |
| Acrolein | affects cotreatment, increases oxidation, increases abundance | 1 |
| Ethanol | affects cotreatment, increases abundance, increases expression | 1 |
| Atrazine | increases expression | 1 |
| Vehicle Emissions | affects expression, increases abundance | 1 |
| Cadmium | decreases expression | 1 |
| Doxorubicin | decreases expression | 1 |
| Estradiol | increases expression | 1 |
| Folic Acid | decreases expression | 1 |
| Gasoline | increases expression, affects cotreatment, increases abundance | 1 |
| Methotrexate | affects response to substance | 1 |
| Polycyclic Aromatic Hydrocarbons | affects cotreatment, increases abundance, increases expression | 1 |
| Rotenone | increases expression | 1 |
| Smoke | decreases expression | 1 |
| Valproic Acid | increases methylation | 1 |
Cellosaurus cell lines
1 cell lines: 1 transformed cell line
First 10 cell lines (id-ordered, not curated):
| Cellosaurus | Name | Category | Sex |
|---|---|---|---|
| CVCL_B3JN | Abcam HEK293T TMEM259 KO | Transformed cell line | Female |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.